-
How can patients with cerebral hemorrhage address blood pressure variability? Nicardipin may be preferred
Time of Update: 2022-09-21
Figure 1 Comparison of mean BPV between different treatment regimensFrom this study, it can be seen that compared with labetalol or hydralazine, nicardipine can lower blood pressure more stably after spontaneous intracerebral hemorrhage, avoiding the adverse effects of excessive BPV on the prognosis of patients.
-
Professor Zhou Qing: Precise and powerful, long-lasting brain control, loratinib first-line treatment of Asian patients data is remarkable
Time of Update: 2022-09-21
*For medical professionals onlyBig coffee shared the results of Crown's study on Asian populations, looking forward to the application prospects of loratinib in ALK-positive NSCLC patients in China.
-
"Two birds with one stone"——The role of sulfonylureas in the treatment of "periodontitis-diabetes" comorbidity
Time of Update: 2022-09-06
In addition, if sulfonylureas are used as drugs for the treatment of periodontitis-diabetes complications, they can achieve the effect of "killing two birds with one stone" .
-
Cinova URAT1 new gout drug pivotal Phase II data announced, aiming at Best-in-class
Time of Update: 2022-02-20
In 2019, XNW3009 conducted the first clinical study in Australia; in March 2021, Sinovate announced that XNW3009 tablets can reduce uric acid in patients with hyperuricemia (with or without gout) on the drug clinical trial registration and information publicity platform A multicenter, randomized, double-blind, benzbromarone-controlled, parallel-group phase II clinical study of efficacy and safety .
-
J Immunother Cancer: The efficacy of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma
Time of Update: 2022-01-23
Therefore, a team from the First Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the efficacy of PD-1 inhibitor combined with chemotherapy in neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma .
-
Nuocheng Jianhua's new TYK2 inhibitor ICP-332 completes the first subject administration
Time of Update: 2021-08-28
ICP-332 is a class 1 innovative drug with global independent intellectual property rights of Nuocheng Jianhua, and it is a new type of oral TYK2 inhibitor .
-
PNAS: how regulatory T cells regulate the autoimmune response of the central nervous system
Time of Update: 2021-06-08
The results showed that although there was no significant difference in the number of Treg cells in the CNS region of icKO and wild-type mice, the expression levels of CTLA-4 and Blimp-1 of Treg cells in mutant mice were significantly down-regulated, and their activation levels were also affected.
-
The Lancet reveals that Remegis is safe and effective in preventing migraines
Time of Update: 2021-03-08
The team conducted a multicenter, randomized, double-blind, placebo-controlled trial at 92 research centers in the United States to assess the safety and effectiveness of remegis in migraine prevention treatment.
-
NEJM: Early plasma therapy during high-titration recovery can reduce the risk of worsening the disease of infected people with neo-crown pneumonia in old age
Time of Update: 2021-01-13
, for patients with mild neocephaly, receiving high antibody titration recovery plasma within 72 hours of onset can effectively reduce the risk of worsening symptoms in elderly patients.
-
Lancet oncol: Effects of preoperative radiotherapy on prognosis in patients with postmenal sarcoma
Time of Update: 2020-10-04
study aims to assess the effects of preoperative radiotherapy combined surgery and simple surgery on the recurrence of re-occurrence prognosis in patients with abdominal sarcoma.
30 (24%) and 13 (10%) severe adverse reactions occurred in the joint group and the single surgical group, respectively.
-
JAMA Oncol: PD-L1 and CTLA-4 double inhibition may improve survival in patients with advanced colon cancer
Time of Update: 2020-05-29
In addition to patients with high microsatellite instability (MSI-H), PD-L1 monoantigen was not effective in patients with advanced refractory colorectal cancer (CRC), and recently researchers exam
-
Ampion in the treatment of knee osteoarthritis stage III clinical success
Time of Update: 2017-12-18
Source: Sina Pharmaceutical News 2017-12-18 ampio Pharma is a biopharmaceutical company focused on developing innovative therapies for the treatment of inflammatory diseases with very limited selectio
-
Zhao Zhigang: using 18 indexes to evaluate the quality difference of infusion products
Time of Update: 2016-05-20
Source: xinhua.com May 20, 2016 China is a big infusion country, the quality of infusion products is directly related to the life and health of the people With the development of science and technolog
